Clinical trial
Vinorelbine in Treating Patients With Metastatic Prostate Cancer
NCT00003259 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003259 |
|---|---|
| Title | Vinorelbine in Treating Patients With Metastatic Prostate Cancer |
| Official title | Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma Phase II Trials Protocol 4: Vinorelbine |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | vinorelbine tartrate |
| Enrollment | 40 |
| Start date | Oct 1, 1997 |
| Primary completion | Sep 1, 1999 |
| Completion | Sep 1, 1999 |
| First posted | Aug 2, 2004 |
| Last update posted | Jun 26, 2019 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: